Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 114.90M | 6.59M | 2.23M | 5.20M | 0.00 | 0.00 |
Gross Profit | 114.90M | 6.59M | 2.23M | -4.87M | -4.58M | -1.75M |
EBITDA | -9.24M | -111.47M | -121.21M | -119.34M | -89.92M | -51.44M |
Net Income | -21.95M | -126.57M | -136.67M | -130.93M | -95.82M | -54.66M |
Balance Sheet | ||||||
Total Assets | 315.61M | 353.22M | 360.69M | 486.54M | 437.38M | 106.78M |
Cash, Cash Equivalents and Short-Term Investments | 165.12M | 189.29M | 172.74M | 315.50M | 222.88M | 75.75M |
Total Debt | 47.79M | 53.83M | 48.17M | 49.41M | 23.46M | 21.55M |
Total Liabilities | 75.17M | 191.85M | 175.94M | 183.81M | 41.14M | 213.19M |
Stockholders Equity | 240.44M | 161.36M | 184.75M | 302.74M | 396.24M | -106.41M |
Cash Flow | ||||||
Free Cash Flow | -114.13M | -110.29M | -102.08M | -16.55M | -133.97M | -51.09M |
Operating Cash Flow | -114.51M | -110.14M | -88.35M | 14.05M | -89.00M | -41.27M |
Investing Cash Flow | 63.87M | 47.48M | 61.13M | -13.13M | -298.34M | -22.76M |
Financing Cash Flow | 56.49M | 74.56M | -9.72M | 27.16M | 417.77M | 47.69M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $53.65M | ― | -59.49% | ― | 21.15% | 46.44% | |
50 Neutral | $48.46M | ― | -10.49% | ― | 8286.79% | 87.23% | |
49 Neutral | AU$2.52B | 3.19 | -57.47% | 2.78% | 36.73% | 13.67% | |
47 Neutral | $45.26M | ― | -232.51% | ― | 138.11% | 76.60% | |
44 Neutral | $26.91M | ― | -83.73% | ― | ― | 42.39% | |
42 Neutral | $38.77M | ― | -71.90% | ― | 69.65% | 27.98% | |
35 Underperform | $45.37M | ― | -101.34% | ― | ― | 21.40% |
On July 1, 2025, Century Therapeutics‘ Board of Directors approved a significant reduction in force, cutting approximately 51% of its workforce to concentrate on high-potential programs. The company anticipates incurring around $3.7 million in severance and related costs, with the reduction expected to be largely completed by the end of the third quarter of 2025.
The most recent analyst rating on (IPSC) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.
On June 12, 2025, Century Therapeutics, Inc. conducted its 2025 Annual Meeting of Stockholders virtually. During the meeting, Daphne Quimi and Carlo Rizzuto, Ph.D. were elected as Class I directors to serve until the 2028 Annual Meeting. Additionally, Ernst & Young LLP’s appointment as the company’s independent registered public accounting firm for the 2025 fiscal year was ratified. These decisions reflect the company’s ongoing efforts to strengthen its governance and ensure financial oversight, potentially impacting its strategic direction and stakeholder confidence.
The most recent analyst rating on (IPSC) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.
On May 15, 2025, Century Therapeutics reported its first-quarter financial results and provided a business update. The company initiated patient dosing in the Phase 1 CALiPSO-1 trial for CNTY-101 in the U.S., with plans to expand to Europe. Century is also preparing to start IND-enabling studies for CNTY-308 in mid-2025. Financially, the company reported a net income of $76.6 million for the quarter, significantly up from a net loss in the same period last year, largely due to collaboration revenue from a terminated agreement with Bristol-Myers Squibb.
The most recent analyst rating on (IPSC) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.